221 related articles for article (PubMed ID: 17602226)
1. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.
Fujihara A; Kurooka M; Miki T; Kaneda Y
Cancer Immunol Immunother; 2008 Jan; 57(1):73-84. PubMed ID: 17602226
[TBL] [Abstract][Full Text] [Related]
2. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
Kurooka M; Kaneda Y
Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703
[TBL] [Abstract][Full Text] [Related]
3. [Anticancer immunotherapy using inactivated Sendai virus particles].
Kurooka M; Kaneda Y
Uirusu; 2007 Jun; 57(1):19-27. PubMed ID: 18040151
[TBL] [Abstract][Full Text] [Related]
4. Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells.
Li S; Nishikawa T; Kaneda Y
Cancer Sci; 2017 Dec; 108(12):2333-2341. PubMed ID: 28945328
[TBL] [Abstract][Full Text] [Related]
5. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
6. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.
Matsuda M; Nimura K; Shimbo T; Hamasaki T; Yamamoto T; Matsumura A; Kaneda Y
J Neurooncol; 2011 May; 103(1):19-31. PubMed ID: 20730616
[TBL] [Abstract][Full Text] [Related]
7. Inactivated Sendai virus suppresses murine melanoma growth by inducing host immune responses and down-regulating β-catenin expression.
Zhang Q; Yuan WF; Zhai GQ; Zhu SY; Xue ZF; Zhu HF; Xu XM
Biomed Environ Sci; 2012 Oct; 25(5):509-16. PubMed ID: 23122307
[TBL] [Abstract][Full Text] [Related]
8. Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-γ production.
Saga K; Tamai K; Yamazaki T; Kaneda Y
Clin Cancer Res; 2013 Feb; 19(3):668-79. PubMed ID: 23251005
[TBL] [Abstract][Full Text] [Related]
9. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle.
Kawaguchi Y; Miyamoto Y; Inoue T; Kaneda Y
Int J Cancer; 2009 May; 124(10):2478-87. PubMed ID: 19173282
[TBL] [Abstract][Full Text] [Related]
10. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon.
Tanaka M; Shimbo T; Kikuchi Y; Matsuda M; Kaneda Y
Int J Cancer; 2010 Apr; 126(8):1982-1991. PubMed ID: 19830690
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.
Fujita K; Nakai Y; Kawashima A; Ujike T; Nagahara A; Nakajima T; Inoue T; Lee CM; Uemura M; Miyagawa Y; Kaneda Y; Nonomura N
Cancer Gene Ther; 2017 Jul; 24(7):277-281. PubMed ID: 28497777
[TBL] [Abstract][Full Text] [Related]
12. Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.
Zhang J; Zhou Z; Wang C; Shen J; Zheng Y; Zhang L; Wang J; Xia D
Cancer Immunol Immunother; 2011 Apr; 60(4):559-73. PubMed ID: 21240488
[TBL] [Abstract][Full Text] [Related]
13. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.
Kawano H; Komaba S; Kanamori T; Kaneda Y
BMC Med; 2007 Sep; 5():28. PubMed ID: 17883878
[TBL] [Abstract][Full Text] [Related]
14. Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application.
Tanemura A; Kiyohara E; Katayama I; Kaneda Y
Cancer Gene Ther; 2013 Nov; 20(11):599-605. PubMed ID: 24157924
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma.
Takehara Y; Satoh T; Nishizawa A; Saeki K; Nakamura M; Masuzawa M; Kaneda Y; Katayama I; Yokozeki H
Clin Immunol; 2013 Oct; 149(1):1-10. PubMed ID: 23886549
[TBL] [Abstract][Full Text] [Related]
16. Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity.
Chang CY; Tai JA; Li S; Nishikawa T; Kaneda Y
Oncotarget; 2016 Jul; 7(27):42195-42207. PubMed ID: 27259252
[TBL] [Abstract][Full Text] [Related]
17. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles.
Matsushima-Miyagi T; Hatano K; Nomura M; Li-Wen L; Nishikawa T; Saga K; Shimbo T; Kaneda Y
Clin Cancer Res; 2012 Nov; 18(22):6271-83. PubMed ID: 23014529
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis in hormone-resistant human prostate cancer PC3 cells by inactivated Sendai virus.
Gao H; Gong XC; Chen ZD; Xu XS; Zhang Q; Xu XM
Biomed Environ Sci; 2014 Jul; 27(7):506-14. PubMed ID: 25073909
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study.
Kiyohara E; Tanemura A; Nishioka M; Yamada M; Tanaka A; Yokomi A; Saito A; Sakura K; Nakajima T; Myoui A; Sakurai T; Kawakami Y; Kaneda Y; Katayama I
Cancer Immunol Immunother; 2020 Jun; 69(6):1131-1140. PubMed ID: 32047956
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands.
Wendel M; Galani IE; Suri-Payer E; Cerwenka A
Cancer Res; 2008 Oct; 68(20):8437-45. PubMed ID: 18922917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
